Scancell Holdings Company Description

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease.

Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.

It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens.

In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus.

Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Scancell Holdings plc

Country	United Kingdom
Founded	1997
Industry	Biotechnology
Sector	Healthcare
Employees	61
CEO	Phillip L'Huillier

Contact Details

Address: Bellhouse Building Oxford, OX4 4GD United Kingdom
Phone	44 18 6558 2066
Website	scancell.co.uk

Stock Details

Ticker Symbol	SCNLF
Exchange	OTCMKTS
Fiscal Year	May - April
Reporting Currency	GBP
ISIN Number	GB00B63D3314
SIC Code	2836

Key Executives

Name	Position
Dr. Phillip John L'Huillier	Chief Executive Officer and Director
Prof. Lindy Gillian Durrant Ph.D.	Chief Scientific Officer and Director and Founder
Sathijeevan Nirmalananthan	Chief Financial Officer, Company Secretary and Director
Dr. Samantha Paston Ph.D.	Head of Translational Research
Dr. Adrian Parry Ph.D.	Head of Manufacturing
Dr. Mandeep Sehmi	Head of Business Development
Dr. Callum Scotthasbeen	Head of Development
Alex Hayward	Head of Finance
Dr. Nermeen Varawalla DPhil, M.B.A., M.D., MBA, Ph.D.	Chief Medical Officer